BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29274828)

  • 1. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
    Fu S; Lairson DR; Chan W; Wu CF; Ramondetta L
    Gynecol Oncol; 2018 Feb; 148(2):342-348. PubMed ID: 29274828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.
    Fu S; Fokom Domgue J; Chan W; Zhao B; Ramondetta LM; Lairson DR
    J Low Genit Tract Dis; 2019 Apr; 23(2):102-109. PubMed ID: 30907776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
    Lairson DR; Fu S; Chan W; Xu L; Shelal Z; Ramondetta L
    Gynecol Oncol; 2017 Apr; 145(1):108-113. PubMed ID: 28196673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
    Insinga RP; Ye X; Singhal PK; Carides GW
    Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States.
    Wu CF; Xu L; Fu S; Peng HL; Messick CA; Lairson DR
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1156-1164. PubMed ID: 30362917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.
    Hampl M; Huppertz E; Schulz-Holstege O; Kok P; Schmitter S
    BMC Infect Dis; 2011 Mar; 11():73. PubMed ID: 21426562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States.
    Prabhu V; Kathe N; Saxena K; Walia A; Markan R; Myers E; Einstein M
    Curr Med Res Opin; 2021 Sep; 37(9):1599-1607. PubMed ID: 34018457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
    Olsen J; Jørgensen TR; Kofoed K; Larsen HK
    BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States.
    Lairson DR; Wu CF; Chan W; Fu S; Hoffman KE; Pettaway CA
    Urol Oncol; 2019 Apr; 37(4):294.e17-294.e25. PubMed ID: 30660492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological and economic burden of potentially HPV-related cancers in France.
    Abramowitz L; Lacau Saint Guily J; Moyal-Barracco M; Bergeron C; Borne H; Dahlab A; Bresse X; Uhart M; Cancalon C; Catella L; Bénard S
    PLoS One; 2018; 13(9):e0202564. PubMed ID: 30235216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of HPV-associated female genital cancers in the United States, 1999-2004.
    Watson M; Saraiya M; Wu X
    J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic and temporal variations in the incidence of vulvar and vaginal cancers.
    Bray F; Laversanne M; Weiderpass E; Arbyn M
    Int J Cancer; 2020 Nov; 147(10):2764-2771. PubMed ID: 32410226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas.
    Zhao B; Fu S; Wu CF; Dahlstrom KR; Fokom Domgue J; Tam S; Xu L; Sturgis EM; Lairson DR
    Oral Oncol; 2019 Sep; 96():21-26. PubMed ID: 31422209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Care Cost of Oropharyngeal Cancer among Texas Patients.
    Lairson DR; Wu CF; Chan W; Dahlstrom KR; Tam S; Sturgis EM
    Cancer Epidemiol Biomarkers Prev; 2017 Sep; 26(9):1443-1449. PubMed ID: 28838945
    [No Abstract]   [Full Text] [Related]  

  • 17. Vulvar and vaginal cancers and dysplasia in France--an analysis of the hospital medical information system (PMSI) database.
    Rémy V; Mathevet P; Vainchtock A
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):210-4. PubMed ID: 19735968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
    Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients.
    Tam S; Wu CF; Peng HL; Dahlstrom KR; Sturgis EM; Lairson DR
    Laryngoscope; 2020 May; 130(5):1186-1194. PubMed ID: 31194270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of Parkinson's disease in a privately insured population.
    Johnson SJ; Kaltenboeck A; Diener M; Birnbaum HG; Grubb E; Castelli-Haley J; Siderowf AD
    Pharmacoeconomics; 2013 Sep; 31(9):799-806. PubMed ID: 23907717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.